Floatz logo

sb-497115-gr

Adult Acute Basophilic Leukemia

Case Comprehensive Cancer CenterPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Adult Acute Basophilic Leukemia cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 3BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BB
Idarubicine
National Cancer Institute (NCI)
Phase 2BB

View all 22 →

Same molecule, other indications

sb-497115-gr is also rated in:

thrombocytopeniaDormant
BB
Indicative ·
71 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
59 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →